Pasadena, CA, United States of America

Wei Dang

USPTO Granted Patents = 32 


 

Average Co-Inventor Count = 7.0

ph-index = 16

Forward Citations = 1,384(Granted Patents)


Company Filing History:


Years Active: 2008-2023

Loading Chart...
Loading Chart...
Loading Chart...
32 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Wei Dang in Biopharmaceuticals

Introduction: Wei Dang, based in Pasadena, CA, is a prominent inventor with an impressive portfolio of 32 patents. His work primarily focuses on biopharmaceutical innovations, developing novel Fc variants to enhance therapeutic applications.

Latest Patents: Wei's recent patents include advancements such as optimized Fc variants, which describe Fc polypeptides with decreased affinity for FcγRIIb. These innovations provide methods for their generation and application, enhancing their effectiveness in diverse therapeutic contexts. Furthermore, he has developed Fc variants with increased affinity for FcγRIIc, accompanied by methods for their generation and practical applications, reinforcing his commitment to advancing biopharmaceutical technology.

Career Highlights: Wei Dang has established himself as a significant contributor to the field of biopharmaceuticals through his extensive patent portfolio. His research and inventions are crucial in improving the specificity and efficacy of therapeutic antibodies, significantly impacting drug development processes.

Collaborations: Wei collaborates with talented colleagues such as Gregory Alan Lazar and Sher Bahadur Karki at Xencor, Inc. Together, they work on innovative projects that push the boundaries of current biopharmaceutical technologies.

Conclusion: Wei Dang's contributions to the field of biopharmaceuticals, demonstrated through his 32 patents and collaborative efforts, highlight his role as a leading innovator. His work continues to advance the development of targeted therapies, showcasing the potential of Fc variants in improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…